NL-OMON55289招募中不适用
Immunity against SARS-CoV-2 in immune-suppressed patients: increased risk of insufficient immunological memory or sufficient protection against re-infection? A Target to B! substudy - T2B! immunity after SARS-CoV-2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 5,350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •fase 1: auto-immune disease, treatment with at least one immunosuppressive
- •medication, SARS-CoV-2 infection
- •fase 2/group 1:auto-immune disease
- •fase 2/group 2: healthy control
排除标准
- •Known pregnancy during study entry. Concomitant treatment with
- •immunosuppressive medication (like chemotherapy) for cancer or
- •organ-transplantation (including stem-cell transplantation).
研究者
相似试验
已完成
Unknown
T2B! immunity after SARS-CoV-2<p>SARS-CoV-2, auto-immune diseases,</p>10003816NL-OMON23600ZonMw3,361
已完成
不适用
Investigation of the immune status against SARS-CoV-2 of medical professionals in Doctor's Practices in Thuringia (COVID-19 research project)SPECIFIC METHODS OF INVESTIGATION FOR SARSCOV2COVID19 VIRUS NOT CONFIRMED COVID19 O.N.A.U99.0U07.2COVID-19, virus not identifiedDRKS00021815Kassenärztliche Vereinigung Thüringen5,773
招募中
不适用
SARS-CoV-2 specific immunity in persons with a primary immune deficiencyPrimary Immune DeficiencyNL-OMON24202eiden University Medical Center10
已完成
不适用
SARS-CoV-2 specific immunity in patients with congenital immune deficienciesNL-OMON50905Academisch Medisch Centrum15
已完成
不适用
Baseline immunity to SARS-CoV-2 (COVID-19) in the German population.COVID19U07.1COVID-19, virus identifiedDRKS00029693Institut für Virologie/Universitätsklinikum Bonn15,941